In this review:
Pembrolizumab + chemotherapy for metastatic triple-negative breast cancer
Pembrolizumab + chemotherapy for cervical cancer
Atezolizumab after adjuvant chemotherapy in stage IB-IIIA NSCLC
Pembrolizumab after complete resection of high-risk stage II melanoma
Nivolumab + chemotherapy or ipilimumab for gastric cancers
Vaccination against SARS-CoV-2 in tumour patients
Oncology workforce survey during COVID-19
Problems and unmet needs of cancer survivors
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer
Abiraterone acetate + prednisolone and ADT for prostate cancer
Please login below to download this issue (PDF)